Investors House reported Q2 revenues of EUR 1.9m, 5% below our estimate, mainly owing to weaker top ...
Det andra kvartalet har präglats av låg riskvilja och ett återhållsamt klimat för kapitalanskaffning...
Redeye comments on Medivir’s second quarter report
Redeye’s view on the case remains intact and our forecasts on group level are virtually unchanged.
Inission delivered a decent Q2 report with strong sales and earnings growth, but negative cash flow ...
Redeye raises its forecasts and Base Case slightly following a Q2 report beating our forecasts somew...
Redeye comments on Ultimovacs’ Q2 2022 report with several potential catalysts on the near- to mediu...
DevPort levererar ytterligare ett imponerande kvartal med hög organisk tillväxt under god lönsamhet.
Redeye recognizes that Heliospectra currently is in a phase of transition.
EQL Pharma fortsätter växa kärnverksamheten i hög takt där tillväxten uppgick till 33 procent för kv...
Fordon växer 15% organiskt Nettoomsättningen i Q2’22 uppgick till 76,0 mkr (74,5 mkr i Q2’21), vilke...
Tuffare omvärld tynger annonsmarknaden Totala intäkter för Q2 var 33 mkr, vilket var 8% lägre y/y.
Redeye is positive about the clinical study results showing that a low dose of phenylcapsaicin likel...
Redeye’s expectations were only slightly higher than reported Q2 numbers on group level.
Reported EBITA of SEK 28m, +74% vs. ABGSCe Back to normal sooner than expected Share trading at 8x E...
EcoRub meddelade den 18 augusti att bolaget lanserar EcoTPEsuperTM vilket är ett unikt cirkulärt alt...
Endomines saw good development on the production front in Finland in H1.
Redeye raises its full-year sales estimates for 2022E from EUR 7.
Redeye leaves a comment on the Q2 report published by Egetis Therapeutics earlier this morning.
Taaleri reported Q2 EBIT of EUR 2.4m, coming clearly below Refinitiv consensus at EUR 5.
